Navigation Links
DURECT Reports Data From European Phase IIb Shoulder Study of POSIDUR™ (SABER™-Bupivacaine) and Amendment of the Nycomed Agreement
Date:2/9/2011

g candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.

DURECT Forward-Looking Statement

The statements in this press release regarding the potential uses and benefits of POSIDUR and our and our partners intended activities relating to POSIDUR, including our expectation of completing enrollment of the U.S. Phase III program in the first half of 2011 and the potential for Nycomed to continue funding development activities for POSIDUR are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements.  Potential risks and uncertainties include, but are not limited to, our ability to enroll the BESST trial in a timely basis, our and Hospira's ability to conduct and complete on-going clinical trials or to design and enroll additional clinical trials, if any, required for regulatory approval, failure of such clinical trials to produce intended results, Nycomed's evaluation of the results of the BESST trial and their decision whether to continue development and funding of POSIDUR, which is in their sole discretion, possible adverse events associated with the use of POSIDUR, delays and costs due to additional work or other requirements imposed by regulatory agencies for continued development, approval or sale of POSIDUR, our ability to complete the design, development, and manufacturing process development of POSIDUR, and to manufacture, commercialize and obtain marketplace acceptance of POSIDUR, and avoid infringing patents held by other parties and secure and defend patents of our own, and manage and obtain capital to fund our growth, operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-Q filed on November 4, 2010 under the heading "Risk Factors.


'/>"/>
SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. DURECT Announces Positive ELADUR(TM) Phase IIa Study Results
2. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
3. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
4. DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call
5. DURECT to Present at the 21st Annual Piper Jaffray Health Care Conference
6. DURECT Corporation Invites You to Join Its Fourth Quarter 2009 Earnings Conference Call
7. DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory
8. DURECT Corporation Announces Fourth Quarter and Year End 2009 Financial Results
9. DURECT to Present at the Cowen and Company Healthcare Conference
10. DURECT to Present at the Barclays Capital Global Healthcare Conference
11. DURECT Corporation Invites You to Join Its First Quarter 2010 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015 Former NASA ... News online last week where he discussed Theradome™, the ... be FDA-cleared. The FOX segment shows firsthand how, via ... affordable hair loss solution that will not require surgery ... the mitochondria at the base of the hair follicle, ...
(Date:5/4/2015)... 4, 2015 RadiologyAuction will have their first auction ... product demonstrations at the end of the auction on ... Kodak and Fuji Cr,s, Agfa and Sony, printers and ... event. Various imaging equipment will be available at later ... After years of buying and selling imaging equipment, the ...
(Date:5/4/2015)... , May 4, 2015  Oncobiologics, Inc., ... monoclonal antibody (mAb) biosimilars, has completed the construction ... its headquarters in Cranbury, New Jersey ... facility is designed to utilize multiple ... at commercial scale.  Through the use of the ...
Breaking Medicine Technology:FOX News Features Theradome as the Take-Home Solution to Tackle Baldness 2RadiologyAuction Announces Event Starting On May 5th 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 3
... DEERFIELD, IL, June 04, 2007,/PRNewswire-FirstCall/ - Cardiome ... US, Inc. ("Astellas") today,announced results from their ... 2. The trial evaluated the efficacy and ... (iv)") for the treatment of patients who ...
... -- ZymoGenetics,Inc. today announced that interim findings were ... in B-cell chronic,lymphocytic leukemia (B-CLL) at the American ... study included intravenous,administration of higher doses than had ... atacicept was well-tolerated and biologically,active at all dose ...
Cached Medicine Technology:Cardiome And Astellas Announce Positive Results From ACT 2 Trial 2Cardiome And Astellas Announce Positive Results From ACT 2 Trial 3Cardiome And Astellas Announce Positive Results From ACT 2 Trial 4Cardiome And Astellas Announce Positive Results From ACT 2 Trial 5Cardiome And Astellas Announce Positive Results From ACT 2 Trial 6ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia 2ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia 3
(Date:5/4/2015)... The University of California, Davis and ... initiative at UC Davis School of Medicine dedicated ... to advancing Latino health. , The program, called ... to Be Physicians, (“Prep Médico” for short) is ... and internship opportunities, a residential program, intensive language ...
(Date:5/4/2015)... Each year, the Susan G. Komen organization hosts ... for breast cancer. This year, Dr. Mark Deutsch and his ... entertainment sponsor for the 25th annual Susan G. Komen Greater ... Lenox Square Mall. , The Komen organization hopes have 10,000 ... million. Perimeter Plastic Surgery has not only taken on the ...
(Date:5/4/2015)... PROVIDENCE, R.I. (PRWEB) May 04, 2015 Johnson ... new $40 million engineering and science academic center on Wednesday, ... in the ground for land made available by the re-alignment ... at the corner of Friendship and Chestnut streets in Providence, ... being built on a parcel of land the university purchased ...
(Date:5/4/2015)... The Lymphoma Research Foundation (LRF) – ... innovative lymphoma research and serving the lymphoma community through ... patient services – is set to host its annual ... West Orange, NJ on June 1, 2015. Since 2010, ... programs through LRF. , This year, the Lymphoma Research ...
(Date:5/4/2015)... Jacksonville, Fla. (PRWEB) May 04, 2015 ... American Heart Association/American Stroke Association’s Get With The ... the Target: Stroke Honor Roll. The award recognizes ... stroke patients receive the most appropriate treatment according ... latest scientific evidence. , To receive the Gold ...
Breaking Medicine News(10 mins):Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 3Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 4Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 5Health News:Perimeter Plastic Surgery Sponsors 2015 Susan G. Komen Greater Atlanta "Race for the Cure" 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3Health News:Lymphoma Research Foundation Set to Host Annual Ace Lymphoma Luncheon at Mayfair Farms in West Orange, NJ 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4
... levels were low, study finds , , WEDNESDAY, Sept. 26 ... protect against heart disease and stroke no matter what ... new study shows. , The incidence of heart attack, ... in the one-fifth of participants in a major trial ...
... The Society for,Protective Coatings is pleased to announce ... approved awarding of certification credits,for industrial hygienists who ... Paint Removal Refresher (C-5) training courses. ABIH is ... of the,field of industrial hygiene and is the ...
... Science and Technology Committee for Holding Health IT ... ... Now!,Coalition, co-chaired by former Sen. John Breaux and former Rep. Nancy,Johnson, called ... "It,s time for Congress to act so that our health care ...
... ARRO ) announced today the final tabulation of votes at ... Proposal 1 -- Shareholders voted to adopt the merger agreement with ... cast voting to approve the merger agreement. ... a positive vote of a majority of shares voting on this ...
... ANA, Calif., Sept. 26 SEIU United ... for injunctive relief seeking,to stop Tenet Healthcare ... California hospital employees, including registered nurses,pharmacists, licensed ... technicians, and certified nursing,assistants. Workers represented ...
... Smith,s National Campaign Ramps ... Lose the First Million, CHICAGO, Sept. 26 Since its launch ... 50 Million Pound,Challenge and have lost more than three-quarters of a million ... hopes,those early adopters will lead the way to a million pounds lost ...
Cached Medicine News:Health News:High HDL Levels Protect Heart Health 2Health News:ABIH Approves Certification Credit for SSPC Training Courses 2Health News:Health IT Now! Coalition Calls on Congress to Pass Health Information Technology Legislation This Year 2Health News:Arrow International Announces Annual Meeting Voting Results 2Health News:Unions File Charges Against Tenet Healthcare Corporation 2Health News:The Challenge: Make It A Million (Pounds Lost That Is) 2Health News:The Challenge: Make It A Million (Pounds Lost That Is) 3
The Compass Commander series is engineered to provide the discriminating neurosurgeon with the same capabilities offered within the commander plus+, all in a smaller, lower-cost package....
Used for access and catheterization procedures. Double flexible tipped design permits alternative use of both ends of wire guide depending upon procedural needs. Supplied sterile in peel-open package...
Used for access and catheterization procedures. Double flexible tipped design permits alternative use of both ends of wire guide depending upon procedural needs. Supplied sterile in peel-open package...
... The MULTI-LINK VISION Coronary Stent System ... of cobalt chromium stents. Cobalt chromium is ... so a cobalt chromium stent can have ... stainless steel stent with struts that are ...
Medicine Products: